NEW YORK ( TheStreet) -- Meridian Bioscience (Nasdaq: VIVO) hit a new 52-week high Thursday as it is currently trading at $25.54, above its previous 52-week high of $25.06 with 18,819 shares traded as of 9:32 a.m. ET. Average volume has been 176,700 shares over the past 30 days.

Meridian Bioscience has a market cap of $1 billion and is part of the health care sector and drugs industry. Shares are up 6.8% year to date as of the close of trading on Wednesday.

Meridian Bioscience, Inc. operates as an integrated life science company. The company primarily engages in the development, manufacture, sale, and distribution of diagnostic test kits primarily for respiratory, gastrointestinal, viral, and parasitic infectious diseases. The company has a P/E ratio of 40.4, above the average drugs industry P/E ratio of 39.8 and above the S&P 500 P/E ratio of 17.7.
  • Practice your VIVO trading strategies and win cash in our stock game.

TheStreet Ratings rates Meridian Bioscience as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, growth in earnings per share and expanding profit margins. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. You can view the full Meridian Bioscience Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

If you liked this article you might like

3 Undiscovered, Undervalued Health Care Stocks Poised to Outperform the Sector in 2016

Insider Trading Alert - VIVO, CCG And PDCE Traded By Insiders

Meridian Bioscience (VIVO) Weak On High Volume

Buy These 4 High-Yield Dividend Stocks to Take Advantage of the Health Care Boom

Meridian Bioscience (VIVO) Upgraded From Hold to Buy